Frontiers in Endocrinology (Dec 2023)

Analysis and prediction of 5-year survival in patients with cutaneous melanoma: a model-based period analysis

  • Suzheng Zheng,
  • Hai Yu,
  • Xinkai Zheng,
  • U Tim Wu,
  • Wai-kit Ming,
  • Hui Huang,
  • Jiaxin Song,
  • Xiaoxi Zhang,
  • Jun Lyu,
  • Jun Lyu,
  • Liehua Deng,
  • Liehua Deng

DOI
https://doi.org/10.3389/fendo.2023.1238086
Journal volume & issue
Vol. 14

Abstract

Read online

BackgroundThe survival and prognosis of patients are significantly threatened by cutaneous melanoma (CM), which is a highly aggressive disease. It is therefore crucial to determine the most recent survival rate of CM. This study used population-based cancer registry data to examine the 5-year relative survival rate of CM in the US.MethodsPeriod analysis was used to assess the relative survival rate and trends of patients with CM in the Surveillance, Epidemiology, and End Results (SEER) database during 2004–2018. And based on the data stratified by age, gender, race and subtype in the SEER database, a generalized linear model was 12established to predict the 5-year relative survival rate of CM patients from 2019 to 2023.ResultsThe 5-year relative survival increased to various degrees for both total CM and CM subtypes during the observation period. The improvement was greatest for amelanotic melanoma, increasing from 69.0% to 81.5%. The 5-year overall relative survival rates of CM were 92.9%, 93.5%, and 95.6% for 2004–2008, 2009–2013, and 2014–2018, respectively. Females had a marginally higher survival rate than males for almost all subtypes, older people had lower survival rates than younger people, white patients had higher survival rates than nonwhite ones, and urban locations had higher rates of survival from CM than rural locations did. The survival rate of CM was significantly lower for distant metastasis.ConclusionThe survival rate of patients with CM gradually improved overall during 2004–2018. With the predicted survival rate of 96.7% for 2019–2023, this trend will still be present. Assessing the changes experienced by patients with CM over the previous 15 years can help in predicting the future course of CM. It also provides a scientific foundation that associated departments can use to develop efficient tumor prevention and control strategies.

Keywords